NASDAQ · INBX
Inhibrx Biosciences Inc.
$70.55-$3.10 (-4.21%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.57% below the high.
Loading market information…
NASDAQ · SLRN · USD
Stock price, earnings
Quote as of May 21, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acelyrin, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.56+30.86% vs estimate |
| $0.00 |
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$70.55-$3.10 (-4.21%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.57% below the high.
$4.00+$0.01 (+0.25%)
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$8.54-$0.64 (-6.97%)
Catabasis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.27% below the high.
$3.17-$0.25 (-7.31%)
Cytocom, Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.43% below the high.
$15.15+$0.02 (+0.1%)
Merrimack Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
